Issues Concerning Safety of Topical Cosmetics and Nutraceuticals

Living reference work entry
Part of the Clinical Approaches and Procedures in Cosmetic Dermatology book series (CAPCD)

Abstract

There are hundreds of cosmetics and orally taken products not included as drugs in the market, even those that promise an additional therapeutic effect as lightening the skin, improving acne, and smoothing rhytides. The list of nutraceuticals is even greater especially when the so-called dietary supplements are included. There are numbers of papers and health alerts referring dangerous substances that are added to these products; some were exclusive from a specific country, but the globalization led to a mixture of all kinds of them being commercialized all around the world. Alerts should be taken seriously and the population should be also notified about this serious matter. We try to discuss about them, and although the list of substances is enormous and some adverse events yet to be described, it could be of interest to alert the patients about their choice. Each country has a list of forbidden formulations and chemicals; some are very rigorous and others still tolerant. We talk in this chapter the majority of them, but some of the regulatory issues are based in Brazilian ANVISA (National Health Department).

Keywords

Nutraceuticals Cosmetic Adverse events Safety Contact dermatitis 

References

  1. Agencia Nacional de Vigilância Sanitária. 1999. http://portal.anvisa.gov.br/wps/portal/anvisa/home
  2. Berne B, Tammela M, Farm G, Inerot A, Lindberg M. Can the reporting of adverse skin reactions to cosmetics be proved? A prospective clinical study using a structured protocol. Contact Dermatitis. 2008;58:223–7.CrossRefPubMedGoogle Scholar
  3. Bons B, Audebret F, Bitaudeau C. Assessment of undesirable events in cosmetic market surveillance: background, description and use of a causality assessment method in cosmetovigilance. Regul Toxicol Pharmacol. 2010;58:349–53.CrossRefPubMedGoogle Scholar
  4. Di Giovanni C, Arcoraci V, Gambardella L, Sautebin L. Cosmetovigilance survey: are cosmetics considered safe by consumers? Pharmacol Res. 2006;53(1):16–21.CrossRefPubMedGoogle Scholar
  5. Dreno B, et al. The science of dermocosmetics and its role in dermatology. J Eur Acad Dermatol Venereol. 2014;28:1409–17.CrossRefPubMedGoogle Scholar
  6. Dureja H, Kaushik D, Kumar V. Developments in nutraceuticals. Indian J Pharm. 2003;35(6):363–72.Google Scholar
  7. Instituto Nacional do Câncer. 2006. (http://www.inca.gov.br/conteudo_view.asp?ID=795) 16. U.S. National Institute of Cancer: http://www.cancer.gov/cancertopics/factsheet/Risk/formaldehyde.
  8. International Agency for Research Organization. IARC Monographs Carcinogenic Risks to Humans. 2006;88. http://monographs.iarc.fr/ENG/Monographs/vol88/index.php.
  9. International Programme on Chemical Safety (IPS): Chemical Safety Information from Intergovernmental Organizations (INCHEM). 1993. http://www.inchem.org/documents/sids/sids/57136.pdf; http://www.inchem.org/documents/jecfa/jeceval/jec_2374.htm; http://www.inchem.org/documents/icsc/icsc/eics0595.htm.
  10. Krasteva M, et al. Contact allergy to hair colouring products – the cosmetovigilance experience of 4 companies (2003–2006). Eur J Dermatol. 2010;20(1):85–95.PubMedGoogle Scholar
  11. Krecisz B, Chomiczewska-Skóra D, Kiec-Swierczynska M. Preservatives as important etiologic factor of allergic contact dermatitis. Med Pr. 2015;66(3):327–32. doi:10.13075/mp.5893.00176.CrossRefPubMedGoogle Scholar
  12. Lefebvre MA, Meuling WJ, Engel R, Coroama MC, Renner G, Pape W, Nohynek GJ. Consumer inhalation exposure to formaldehyde from the use of personal care products/cosmetics. Regul Toxicol Pharmacol. 2012;63(1):171–6. doi:10.1016/j.yrtph. 2012.02.011. Epub 3 Mar 2012.Google Scholar
  13. Moretti U, Velo G. Cosmetovigilance: the ‘beautiful’ risk. Drug Saf. 2008;31(5):437–9.CrossRefPubMedGoogle Scholar
  14. National Toxicology Program, Department of Health and Human Services. Services Report on Carcinogens, Twelfth Edition. 2011. Formaldehyde (CAS N. 50–00-0): http://ntp.niehs.nih.gov/ntp/roc/twelfth/profiles/Formaldehyde.pdf
  15. Nohynek GJ, Antignac E, Re T, Toutain H. Safety assessment of personal care products/cosmetics and their ingredientes. Toxicol Appl Pharmacol. 2010;243:239–59.CrossRefPubMedGoogle Scholar
  16. Pauwels M, Rogiers V. Human health safety evaluation of cosmetics in the EU: a legally imposed challenge to science. Toxicol Appl Pharmacol. 2010;243(2):260–74.CrossRefPubMedGoogle Scholar
  17. Salverda J, et al. Results of a cosmetovigilance survey in the Netherlands. Contact Dermatitis. 2013;68:139–48.CrossRefPubMedGoogle Scholar
  18. Sautebin L. A cosmetovigilance survey in Europe. Pharmacol Res. 2007;55(5):455–60.CrossRefPubMedGoogle Scholar
  19. U.S. Department of Labor. Occupational Safety and Health Administration. 2011. http://www.osha.gov/SLTC/formaldehyde/index.html.
  20. Vigan M, Castelain F. Cosmetovigilance: definition, regulation and use “in practice”. Eur J Dermatol. 2014;24(6):643–9.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Serviço de DermatologiaHospital Naval Marcílio DiasRio de JaneiroBrazil
  2. 2.Clínicas Hospital of São Paulo of the University of Sao PauloSao PauloBrazil
  3. 3.Barradas and Bourroul’s Ambulatório de Especialidades in Sao PauloSao PauloBrazil
  4. 4.Sorocaba’s Ambulatório de Especialidade in SorocabaSao PauloBrazil

Personalised recommendations